Acción TGTX TG THERAPEUTICS, INC.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas TG Therapeutics, Inc.

Acciones

TGTX

US88322Q1085

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:00:00 14/06/2024 		Varia. Cinco días. Varia. 1 de enero.
16,55 USD -1,25 % Gráfico intradía de TG Therapeutics, Inc. +4,42 % -3,10 %
13/06 La Asociación de Jubilación de Empleados del Condado de Los Ángeles presenta una declaración de solicitud exenta ante la Comisión de Bolsa y Valores CI
11/06 Transcript : TG Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 01:20 PM

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Los Angeles County Employees Retirement Association Files an Exempt Solicitation Statement with Securities and Exchange Commission
CalSTRS Files an Exempt Solicitation Statement to Shareholders of TG Therapeutics
TG Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
TG Therapeutics Announces Presentations for BRIUMVI in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
TG Therapeutics Announces Schedule of Upcoming Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the 2024 Consortium of Multiple Sclerosis Centers Annual Meeting
Small lymphocytic lymphoma Pipeline, FDA Approvals, Unmet Needs, Preclinical and Discovery Stage Product, and Companies 2024 (Updated)
Wall Street Set to Open Lower Ahead of Fed Rate Decision; Private Employment Figures Top Forecasts
TG Therapeutics: Q1 Earnings Snapshot
Earnings Flash (TGTX) TG THERAPEUTICS Reports Q1 Revenue $63.5M, vs. Street Est of $54.6M
TG Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
TG Therapeutics to Host Conference Call on First Quarter 2024 Financial Results and Business Update
North American Morning Briefing : Investors Brace -2-
TG Therapeutics Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading
Sector Update: Health Care
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción TGTX
  4. Noticias TG Therapeutics, Inc.
  5. Otros idiomas